MARKET

CRBP

CRBP

Corbus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.790
-0.450
-8.59%
After Hours: 4.820 +0.03 +0.63% 16:49 04/01 EDT
OPEN
4.960
PREV CLOSE
5.24
HIGH
5.30
LOW
4.790
VOLUME
714.59K
TURNOVER
--
52 WEEK HIGH
8.09
52 WEEK LOW
3.290
MARKET CAP
347.23M
P/E (TTM)
-4.2525
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CRBP stock price target is 21.83 with a high estimate of 28.00 and a low estimate of 12.00.

EPS

CRBP News

More
  • Edited Transcript of CRBP earnings conference call or presentation 12-Mar-20 12:30pm GMT
  • Thomson Reuters StreetEvents · 18h ago
  • Cannabis Stock Gainers And Losers From March 30, 2020
  • Benzinga · 2d ago
  • RBC sees 21% upside in Danaher in premarket analyst action
  • Seeking Alpha - Article · 6d ago
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36

Industry

Biotechnology & Medical Research
-4.51%
Pharmaceuticals & Medical Research
-2.97%

Hot Stocks

Symbol
Price
%Change

About CRBP

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
More

Webull offers kinds of Corbus Pharmaceuticals Holdings Inc stock information, including NASDAQ:CRBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBP stock news, and many more online research tools to help you make informed decisions.